<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-14T19:38:02Z</responseDate>
  <request identifier="oai:figshare.com:article/34047334" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34047334</identifier>
        <datestamp>2026-10-01T17:22:39Z</datestamp>
        <setSpec>category_8</setSpec>
        <setSpec>category_12</setSpec>
        <setSpec>category_24</setSpec>
        <setSpec>category_272</setSpec>
        <setSpec>category_39</setSpec>
        <setSpec>category_46</setSpec>
        <setSpec>category_734</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>category_134</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_10_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;SARS-CoV-2 variants entry and binding with a library of bat ACE2.&lt;/p&gt;</dc:title>
          <dc:creator>Nazia Thakur (9904162)</dc:creator>
          <dc:creator>Joseph Newman (5638340)</dc:creator>
          <dc:creator>Dongchun Ni (15188356)</dc:creator>
          <dc:creator>Jeffrey Seow (9415776)</dc:creator>
          <dc:creator>Abigail L. Hay (25157576)</dc:creator>
          <dc:creator>Yeonjae Lee (12256119)</dc:creator>
          <dc:creator>Ayush Upadhyay (25157573)</dc:creator>
          <dc:creator>Babatunde E. Ekundayo (25157578)</dc:creator>
          <dc:creator>John A. Hammond (7431785)</dc:creator>
          <dc:creator>Thomas P. Peacock (6536120)</dc:creator>
          <dc:creator>Kelvin Lau (1847764)</dc:creator>
          <dc:creator>Katie J. Doores (346210)</dc:creator>
          <dc:creator>Dalan Bailey (193037)</dc:creator>
          <dc:subject>Microbiology</dc:subject>
          <dc:subject>Cell Biology</dc:subject>
          <dc:subject>Evolutionary Biology</dc:subject>
          <dc:subject>Environmental Sciences not elsewhere classified</dc:subject>
          <dc:subject>Ecology</dc:subject>
          <dc:subject>Immunology</dc:subject>
          <dc:subject>Biological Sciences not elsewhere classified</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>Virology</dc:subject>
          <dc:subject>multiple bat coronaviruses</dc:subject>
          <dc:subject>g ., rc</dc:subject>
          <dc:subject>g ., civet</dc:subject>
          <dc:subject>clade 1 viruses</dc:subject>
          <dc:subject>restricted ace2 usage</dc:subject>
          <dc:subject>mammalian ace2 proteins</dc:subject>
          <dc:subject>g ., rhgb07</dc:subject>
          <dc:subject>using monoclonal antibodies</dc:subject>
          <dc:subject>clade 1 sarbecoviruses</dc:subject>
          <dc:subject>div &gt;&lt; p</dc:subject>
          <dc:subject>determined host range</dc:subject>
          <dc:subject>converting enzyme 2</dc:subject>
          <dc:subject>2 convalescent individuals</dc:subject>
          <dc:subject>ace2 ), via</dc:subject>
          <dc:subject>using binding assays</dc:subject>
          <dc:subject>antigenicity using sera</dc:subject>
          <dc:subject>related bat sarbecoviruses</dc:subject>
          <dc:subject>using sarbecoviruses</dc:subject>
          <dc:subject>host range</dc:subject>
          <dc:subject>clade 3</dc:subject>
          <dc:subject>pangolin ),</dc:subject>
          <dc:subject>neutralising antibodies</dc:subject>
          <dc:subject>entry assays</dc:subject>
          <dc:subject>binding domain</dc:subject>
          <dc:subject>sarbecoviruses interact</dc:subject>
          <dc:subject>sarbecoviruses exhibited</dc:subject>
          <dc:subject>rodent ace2</dc:subject>
          <dc:subject>like rhgb07</dc:subject>
          <dc:subject>generalist ace2</dc:subject>
          <dc:subject>related antigenicity</dc:subject>
          <dc:subject>zoonotic potential</dc:subject>
          <dc:subject>vitally important</dc:subject>
          <dc:subject>still evidence</dc:subject>
          <dc:subject>specialist &lt;/</dc:subject>
          <dc:subject>shifting pattern</dc:subject>
          <dc:subject>robust evidence</dc:subject>
          <dc:subject>research indicates</dc:subject>
          <dc:subject>racoon dog</dc:subject>
          <dc:subject>novel structure</dc:subject>
          <dc:subject>largely maintained</dc:subject>
          <dc:subject>including human</dc:subject>
          <dc:subject>immunodominant target</dc:subject>
          <dc:subject>human primate</dc:subject>
          <dc:subject>generalist phenotypes</dc:subject>
          <dc:subject>generalist &lt;/</dc:subject>
          <dc:subject>especially omicron</dc:subject>
          <dc:subject>entry phenotypes</dc:subject>
          <dc:subject>diverse panel</dc:subject>
          <dc:subject>continued evolution</dc:subject>
          <dc:subject>breakthrough infections</dc:subject>
          <dc:description>&lt;p&gt;&lt;b&gt;(A)&lt;/b&gt; Schematic of the Spike proteins for B.1, Alpha, Delta, Omicron BA.1, Omicron BA.2 and its subvariants BA.4/5, XBB, XBB1.5 and BA.2.86. Key regions of the N-terminal domain (NTD), receptor-binding domain (RBD), S1 and S2 are highlighted and the mutations that arose in these variants have been annotated. The BA.4 and BA.5 Spike is identical, and the difference in XBB1.5 compared to XBB is denoted by an asterisk, which is a reversion of the mutation at position 494 (R493Q). &lt;b&gt;(B)&lt;/b&gt; Infection of HEK293T cells stably expressing hACE2 with SARS-CoV-2, WT and BA.1 pseudoparticles, along with individual mutants generated of these variants at positions 417, 484, 493 and 501, either singly or in combination. Virus was titrated 5-fold on cells and Firefly luciferase signals measured; a negative control (non-enveloped, NE) was also included. The data underlying this Figure can be found in &lt;a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003944#pbio.3003944.s017" target="_blank"&gt;S1 Data&lt;/a&gt;.&lt;/p&gt; &lt;p&gt;(TIF)&lt;/p&gt;</dc:description>
          <dc:date>2026-10-01T17:40:07Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.1371/journal.pbio.3003944.s008</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/_p_SARS-CoV-2_variants_entry_and_binding_with_a_library_of_bat_ACE2_p_/34047334</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
